Hsbc Holdings PLC bought a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 232,926 shares of the medical equipment provider's stock, valued at approximately $14,592,000. Hsbc Holdings PLC owned about 0.06% of Smith & Nephew SNATS at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of Smith & Nephew SNATS in the 2nd quarter valued at $505,323,000. River Road Asset Management LLC increased its holdings in shares of Smith & Nephew SNATS by 13.8% in the fourth quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider's stock worth $103,996,000 after acquiring an additional 384,926 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Smith & Nephew SNATS by 5.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider's stock worth $67,383,000 after purchasing an additional 100,697 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Smith & Nephew SNATS during the second quarter worth $89,325,000. Finally, Dimensional Fund Advisors LP increased its holdings in Smith & Nephew SNATS by 44.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,052,747 shares of the medical equipment provider's stock worth $33,436,000 after purchasing an additional 324,080 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. The Goldman Sachs Group reiterated a "buy" rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Morgan Stanley reiterated an "overweight" rating on shares of Smith & Nephew SNATS in a report on Wednesday, August 5th. Barclays cut shares of Smith & Nephew SNATS from an "equal weight" rating to an "underweight" rating in a research report on Wednesday, August 5th. Finally, Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a report on Monday, May 11th. Two equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Smith & Nephew SNATS currently has an average rating of "Hold" and a consensus price target of $30.93.
View Our Latest Analysis on SNN
Smith & Nephew SNATS Trading Down 0.6%
Shares of SNN stock opened at $29.14 on Friday. The stock's fifty day moving average price is $30.24 and its two-hundred day moving average price is $31.70. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS, Inc. has a fifty-two week low of $28.56 and a fifty-two week high of $38.79.
Smith & Nephew SNATS Announces Dividend
The business also recently declared a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be paid a $0.312 dividend. This represents a dividend yield of 205.0%. The ex-dividend date is Friday, October 2nd.
About Smith & Nephew SNATS
(
Free Report)
Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.
In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.
Featured Articles
Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Smith & Nephew SNATS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.
While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
